0.1 overview

Overview

As part of the Kotak Mahindra Group, we combine our strength of understanding the local environment with international best practices in people, processes and research.

Given the experience and network of relationships built over the past two decades, our understanding of the Indian entrepreneur's mindset provides us with a significant advantage in the Indian investment environment. With a founding team whose members have been pioneers in the Indian private equity industry, we are disciplined investors focused on long-term value creation and growth. We partner with outstanding promoters and leadership teams to help create scale across industries. Through intensive research, we identify

macro-economic trends and opportunities early. Our team has successfully identified sectors and companies much ahead of the curve, helping us invest conservatively and exit profitably while partnering companies in tapping growth opportunities and evolving into industry leaders. The team at Kotak Private Equity has often been amongst the first to invest in India's sunrise sectors such as Life Sciences & Healthcare, Media & Entertainment, Retail, Quick Service Restaurants, Business Process Outsourcing and Internet driven businesses.

Investment Strategy

Discovering Future Leaders - As pioneers of the Indian private equity industry, our team is adept at identifying outstanding entrepreneurs and management teams of emerging businesses. We look for companies that have a clear business strategy with significant opportunities to scale up with a defendable market positioning.

While we have a preference towards sectors such as Pharmaceuticals, Life Sciences, Healthcare, Consumer, Technology & Financial Services, we are happy to evaluate investment opportunities in companies in other sectors with a differentiated business model that mirrors India's growth story.

0.2 our approach

Businesses should ideally have a strong competitive edge and long-term growth or more of the following areas:

Growth opportunities to gain regional or national market leadership

An IPR driven business with technology, product or a clearly differentiated market opportunity

An Innovative business model

We also look for outstanding management teams:

Experienced and passionate people with a disciplined and execution-led approach

Hunger for growth and a collaborative mind-set with due respect to partnerships

High level of integrity

Our Team

0.3 our team

KV Ramakrishnan

CEO – Private Equity

KV Ramakrishna is the Chief Executive Officer of Kotak Private Equity Group (KPEG). He joined the team in October 2004.

Read More

Nitin Deshmukh

Founding Partner – Private Equity

Nitin Deshmukh is the founding member of the Private Equity practice at Kotak and has played a pivotal role in building the Alternate Assets business at Kotak..

Read More

Himanshu Nivsarkar

Executive Director

Himanshu Nivsarkar joined Kotak Private Equity Group (KPEG) in February 2010. Himanshu brings with him diverse work experience of over 17 years...

Read More

Dhiraj Rajendran

Associate Director

Dhiraj Rajendran joined Kotak Private Equity Group (KPEG) in November 2008. Prior to joining KPEG, Dhiraj worked with the mid-market investment...

Read More

Ayan Deb

Associate Vice-President

Ayan Deb joined the Kotak Private Equity Group (KPEG) in July 2017. Prior to joining KPEG, Ayan worked with Nomura India in their...

Read More
0.4 Select Portfolio

Bharat Fritz Werner Ltd.

BFW is the largest manufacturer of CNC machines and machine tools in India. The company manufactures full line of CNC vertical and CNC horizontal machining centers catering to different industry segments. The company has a strong engineering base owing to its German parentage.

Company's customers include several leading companies across industry sectors like Honda Motorcycles, Maruti Udyog, Toyota Kirloskar, L&T, John Deere, M&M, Ashok Leyland, Cummins and Mico-Bosch.

The company adopts a solutions approach whereby it custom designs the machines to suit specific customer requirements and delivers an entire package including an efficient manufacturing process as well as the requisite tools. The company has designed low cost CNC machines for the small and medium enterprises making it one of the largest suppliers to this segment.

Bharat Serums and Vaccines Ltd.

The Mumbai based company has a strong portfolio of niche primary line, life saving injectables for snake bites, rabies, aplastic anemia, meningitis, kala azar, postpartum hemorrhage, and life threatening fungal infections post surgeries and organ transplants. BSV also enjoys good brand equity in the critical area of Infertility with its portfolio of hormones.

BSV is expanding through development and launch of new generation biotech recombinant therapeutic proteins, monoclonal antibodies, difficult generics and Novel Drug Delivery Systems where it is in the process of seeking out licensing opportunities for the global markets. Some of these products ready for out-licensing deals include Liposomal Amphoterecin B a potent anti-fungal agent for serious and life-threatening infections, Pegylated Liposomal Doxorubicin a potent anthracycline-based cytotoxic agent for the treatment of cancer, Goserelin Implants and Leuprolide Injection both indicated for hormone sensitive malignancies and gynecological indications and Recombinant Follicle Stimulating Hormone (FSH) used to induce ovulation and spermatogenesis.

Minda Corporation Ltd.

Minda Corporation Ltd. (MCL), the flagship company of the Ashok Minda Group is one of India's leading automotive components manufacturer with operations across India and Europe spread over 20 plants. Apart from strategically located factories near the important auto hubs in India, it also has operations in Germany, Poland, Czech Republic.

It is the market leader in India with respect to supplying Automotive Security Systems to two wheeler OEMs. It also supplies products like Connective Systems, Plastic interior parts and Die-Casting products to various auto OEMs. MCL caters to large and marquee customers including Bajaj Auto, Tata Motors, TVS Motors, Mahindra & Mahindra, Daimler Benz, Audi, Volkswagen and Fiat.

It also has a large presence in the branded after market segment in India for the products it manufactures.

Manipal Health

Manipal Health is one of India's leading integrated hospital services groups, with a strong presence in the south. It offers tertiary, secondary and primary health care services and has over 4,056 beds across 17 hospitals.

The company owns and operates 11 hospitals with 1,750 beds across eight cities/ towns and provides management consultancy to four hospitals with 2,306 beds. Its flagship hospital in Bangalore offers 60 super-specialties and is rated amongst the best in the country.

The group has a professional strength of over 1,000 doctors, 2,000 clinical staff and 2,800 non-clinical staff. It is currently expanding its owned and operated capacity.

Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited ("AETL") is a large Indian player in Industrial Enzymes.

AETL is one of the few manufacturers in the world that produce a full-spectrum of enzymes derived from all four natural origins - plant, fungal, bacterial and animal, and targets four key industry verticals viz., Human Nutrition, Animal Nutrition, Food Processing and Industrial Processing. The company has a strong R&D team that focuses on developing client/industry specific solutions using its own proprietary enzymes.

The group has a professional strength of over 1,000 doctors, 2,000 clinical staff and 2,800 non-clinical staff. It is currently expanding its owned and operated capacity.

Natco Pharma Ltd.

Natco Pharma Limited ("Natco") is a niche player in pharmaceutical segment in India. The Company has presence across the entire spectrum of pharma value chain - from Drug discovery to pharma retailing. In the Indian market, Natco has leadership position in Oncology segment.

The company is known for launching competitively priced oncology drugs that a larger segment of Indian population could afford. It is the first company in India to receive Compulsory Licensing for an oncology drug. Natco has a growing presence in the US and European market. It has partnered with leading generic companies for marketing of products in developed markets.

Natco has a strong pipeline of generic drugs, many of which have significant revenue potential. The company has a dedicated drug discovery research programme in Oncology.

Natco has 6 modern manufacturing facilities of which 2 have been approved by US FDA.

This website uses cookies to ensure you get the best experience on our website. Learn More. GOT IT!